---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007042"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:31:00.898146+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MindMed FY2022 net loss $56.8M; cash $142.1M; key MM-120 data readouts expected late 2023

## Summary
- Net loss of $56.8M, improved from $93.0M in FY2021; no revenue (clinical-stage biopharma).
- Cash and equivalents $142.1M vs $133.5M; cash runway into first half 2025.
- R&D expenses $36.2M (up $1.4M); G&A $30.2M (down $28.9M, largely due to lower stock comp).
- Phase 2b MM-120 GAD top-line data and Phase 2a MM-120 ADHD data both expected late 2023.
- First clinical trial of MM-402 (R-MDMA for autism) planned for 2023.

## SEC filing metadata
- accession: 0000950170-23-007042
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/0000950170-23-007042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/mnmd-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007042
- JSON: https://secwatch.observer/filing/0000950170-23-007042.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007042.txt

## Key facts
- Earnings Releases
  Definium Therapeutics, Inc. updated its the full-year ended December 31, 2022 guidance (reaffirmed).
  - Period: the full-year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: today reported its financial results for the full-year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/0000950170-23-007042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.